71/100BCelestica stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Celestica is 449.90, 94.1% above the current price of 231.74. Their targets range from 375.00 to 520.00.
Of the 13 firms that rated Celestica in the past 12 months, 13 rate it buy or strong buy, 0 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 375.00 to 520.00, with an average of 449.90.
| Buy | 13 | |
| Hold | 0 | |
| Sell | 0 |
12-month price target
| Highest target | 520.00 |
| Average target | 449.90 |
| Lowest target | 375.00 |
| Current price | 231.74 |
Celestica price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Celestica price target and rating?
How analysts rate Celestica, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
13 of 13 firms rate it buy now, against 10 of 12 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Celestica analyst upgrades, downgrades and price targets
The latest rating change came on 24 August 2026, when UBS upgraded Celestica from Neutral to Buy. Its price target is 430.00, from 410.00. The most recent new target came from Barclays on 28 October 2026: 414.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 28 Oct 2026 | Barclays | Reiterated · Overweight | 406.00 → 414.00 | +2.0% | 276.07 |
| 28 Oct 2026 | Goldman Sachs Michael Ng | — | 475.00 → 435.00 | -8.4% | 276.07 |
| 23 Oct 2026 | BMO Capital Thanos Moschopoulos | — | 450.00 → 400.00 | -11.1% | 263.23 |
| 30 Sept 2026 | Bernstein Daniel Zhu | — | 520.00 | — | 366.47 |
| 15 Sept 2026 | FBN Securities Shebly Seyrafi | — | 375.00 | — | 316.08 |
| 24 Aug 2026 | UBS David Vogt | Upgraded · Neutral → Buy | 410.00 → 430.00 | +4.9% | 296.55 |
| 7 Aug 2026 | Barclays Tim Long | Reiterated · Overweight | 430.00 → 406.00 | -5.6% | 314.53 |
| 29 Jul 2026 | RBC Capital Paul Treiber | — | 440.00 → 450.00 | +2.3% | 328.43 |
| 29 Jul 2026 | CIBC | — | 480.00 → 500.00 | +4.2% | 319.57 |
| 29 Jul 2026 | UBS David Vogt | — | 350.00 → 410.00 | +17.1% | 334.83 |
| 29 Jul 2026 | Barclays | Reiterated · Overweight | 441.00 → 430.00 | -2.5% | 350.20 |
| 29 Jul 2026 | Wolfe Research George Notter | Reiterated · Outperform | 475.00 | — | 350.20 |
| 28 Jul 2026 | Stifel Nicolaus | — | 445.00 → 500.00 | +12.4% | 350.08 |
| 1 May 2026 | Redburn Partners | — | 460.00 | — | 409.59 |
| 29 Apr 2026 | CIBC | — | 360.00 → 480.00 | +33.3% | 367.13 |
| 29 Apr 2026 | RBC Capital Paul Treiber | Reiterated · Outperform | 400.00 → 440.00 | +10.0% | 360.16 |
| 29 Apr 2026 | Susquehanna | Reiterated · Positive | 510.00 | — | 361.71 |
| 29 Apr 2026 | TD Securities | Upgraded · Hold → Buy | 350.00 → 430.00 | +22.9% | 361.71 |
| 29 Apr 2026 | Barclays Tim Long | Reiterated · Overweight | 391.00 → 441.00 | +12.8% | 361.71 |
| 28 Apr 2026 | Goldman Sachs | — | 440.00 → 475.00 | +8.0% | 361.71 |
| 28 Apr 2026 | Stifel Nicolaus Ruben Roy | — | 385.00 → 445.00 | +15.6% | 361.71 |
| 24 Apr 2026 | BMO Capital | Reiterated · Outperform | 370.00 → 450.00 | +21.6% | 405.75 |
| 20 Apr 2026 | TD Securities | Reiterated · Hold | 305.00 → 350.00 | +14.8% | 396.01 |
| 11 Mar 2026 | CIBC Todd Coupland | Reiterated · Outperform | 315.00 → 360.00 | +14.3% | 267.23 |
| 30 Jan 2026 | Barclays | Reiterated · Overweight | 359.00 → 391.00 | +8.9% | 300.00 |
| 14 Nov 2025 | Barclays | Reiterated · Overweight | 357.00 → 359.00 | +0.6% | 292.75 |
Celestica EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Celestica's EPS to grow 62.7% a year until 2028, slower than over the last 5 years (73.0% a year) and the last 3 years (70.9%).
Analysts expect Celestica's revenue to grow 65.1% a year until 2028, faster than over the last 5 years (16.6% a year) and the last 3 years (19.6%).
Revenue
EPS
Does Celestica beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 10.4% off the result, either way, and their revenue estimate 4.3%, over the last 12 quarters.
- EPS beats
- 80 / 113
- Revenue beats
- 78 / 112
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +10.4%
- Since
- December 1998
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 26 Oct 2026 | 2.93 | 3.30 | +12.6% | 5.39B | 5.75B | +6.5% |
| Q2 FY2026 | 27 Jul 2026 | 2.29 | 2.54 | +10.9% | 4.30B | 4.67B | +8.6% |
| Q1 FY2026 | 27 Apr 2026 | 2.08 | 2.16 | +3.8% | 3.97B | 3.98B | +0.2% |
| Q4 FY2025 | 28 Jan 2026 | 1.74 | 1.89 | +8.6% | 3.51B | 3.61B | +2.7% |
| Q3 FY2025 | 27 Oct 2025 | 1.47 | 1.58 | +7.5% | 3.49B | 3.16B | -9.5% |
| Q2 FY2025 | 28 Jul 2025 | 1.24 | 1.39 | +12.1% | 2.76B | 2.89B | +4.7% |
| Q1 FY2025 | 24 Apr 2025 | 1.11 | 1.20 | +8.1% | 2.56B | 2.65B | +3.6% |
| Q4 FY2024 | 29 Jan 2025 | 1.04 | 1.11 | +6.7% | 2.53B | 2.55B | +0.5% |
| Q3 FY2024 | 23 Oct 2024 | 0.94 | 1.04 | +10.6% | 2.50B | 2.50B | -0.0% |
| Q2 FY2024 | 24 Jul 2024 | 0.81 | 0.91 | +12.3% | 2.29B | 2.39B | +4.4% |
| Q1 FY2024 | 24 Apr 2024 | 0.72 | 0.86 | +19.4% | 2.10B | 2.20B | +4.7% |
| Q4 FY2023 | 29 Jan 2024 | 0.68 | 0.76 | +11.8% | 2.08B | 2.20B | +5.7% |
Celestica stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Celestica's earnings grow at the 73.0% a year analysts expect to FY2028, then 15.0% a year, it would earn about 41.53 a share in FY2030. At the P/E it has traded at over the last five years (7.7 to 40.2) that is 320.57 to 1,670.27 a share, or 851.21 at its average P/E of 20.5. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 11.36 | 87.70 | 232.87 | 456.95 |
| FY2027 | 21.85 | 168.66 | 447.84 | 878.78 |
| FY2028 | 31.40 | 242.40 | 643.64 | 1,262.97 |
| FY2029 (extrapolated) | 36.11 | 278.76 | 740.18 | 1,452.41 |
| FY2030 (extrapolated) | 41.53 | 320.57 | 851.21 | 1,670.27 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (7.7, 20.5, 40.2).
Is Celestica stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Celestica's P/E of 21.6 is around the middle of its 5-year range (8.3 to 65.8, median 19.0). It is in line with its own history. Buyers pay more for each point of growth than usual: a PEG of 0.3 on expected growth against 0.3 on its median P/E and past five years' growth. At the median P/E of its peers (33.9 × EPS of 10.72), Celestica's fair value is 363.46; the price, 231.74, is 36.2% below it. Its forward P/E, on the consensus for FY2026, is 20.4.
Fair value on the peers is the median P/E of the US companies of its industry closest in size times its earnings per share of the last twelve months; the ends of the bar are the same earnings at the lowest and highest peer P/E (25.0 and 58.2). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 21.62
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 18.98
- Five-year P/E range
- 8.3 – 65.8
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 20.40
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 0.30
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +94.1%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.